The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) will be useful as a common language to harmonize discussions in precision oncology and could also guide policy and reimbursement decisions, but it is far from perfect. Herein, we highlight how ESCAT can be further improved to increase its utility in clinical and policy decisions.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology
npj Precision Oncology Open Access 23 June 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Szabo, L. Are we being misled about precision medicine? The New York Times https://www.nytimes.com/2018/09/11/opinion/cancer-genetic-testing-precision-medicine.html (2018).
Gyawali, B. Point: the imprecise pursuit of precision medicine: are biomarkers to blame? J. Natl Compr. Canc. Netw. 15, 859–862 (2017).
Levêque, D. Off-label use of targeted therapies in oncology. World J. Clin. Oncol. 7, 253–257 (2016).
Mateo, J. et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 29, 1895–1902 (2018).
Gyawali, B. The OlympiAD trial: who won the gold? Ecancermedicalscience 11, ed75 (2017).
Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
Cherny, N. I. et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann. Oncol. 28, 2340–2366 (2017).
Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 372, 724–734 (2015).
Chapman, P. B. et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann. Oncol. 28, 2581–2587 (2017).
Soria, J.-C. et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N. Engl. J. Med. 378, 113–125 (2018).
Drilon, A. et al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N. Engl. J. Med. 378, 731–739 (2018).
Acknowledgements
The work of the authors is funded by the Laura and John Arnold Foundation. A.S.K. also receives grant support from the Harvard Program in Therapeutic Science and the Engelberg Foundation. The funders had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.S.K. has received unrelated research funding from the FDA Division of Health Communication (2013–2016). B.G. declares no competing interests.
Rights and permissions
About this article
Cite this article
Gyawali, B., Kesselheim, A.S. The promise of ESCAT: a new system for evaluating cancer drug–target pairs. Nat Rev Clin Oncol 16, 147–148 (2019). https://doi.org/10.1038/s41571-018-0110-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-018-0110-3
This article is cited by
-
Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology
npj Precision Oncology (2021)